Fmr LLC Has $479,000 Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Fmr LLC boosted its stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 23.1% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 36,416 shares of the company’s stock after buying an additional 6,822 shares during the period. Fmr LLC owned approximately 0.08% of Y-mAbs Therapeutics worth $479,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in YMAB. China Universal Asset Management Co. Ltd. lifted its stake in Y-mAbs Therapeutics by 66.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock valued at $113,000 after acquiring an additional 3,416 shares in the last quarter. Intech Investment Management LLC bought a new stake in shares of Y-mAbs Therapeutics in the third quarter worth $133,000. SG Americas Securities LLC acquired a new position in Y-mAbs Therapeutics during the third quarter worth $178,000. Principal Financial Group Inc. acquired a new stake in Y-mAbs Therapeutics in the 3rd quarter valued at $267,000. Finally, XTX Topco Ltd bought a new stake in Y-mAbs Therapeutics during the 2nd quarter worth about $297,000. Institutional investors and hedge funds own 70.85% of the company’s stock.

Y-mAbs Therapeutics Trading Down 7.9 %

Y-mAbs Therapeutics stock opened at $8.78 on Thursday. The company has a market capitalization of $393.25 million, a price-to-earnings ratio of -16.26 and a beta of 0.61. The stock’s 50 day moving average is $12.69 and its 200-day moving average is $12.65. Y-mAbs Therapeutics, Inc. has a 12 month low of $6.09 and a 12 month high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The firm had revenue of $18.46 million for the quarter, compared to analyst estimates of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period in the prior year, the business posted ($0.18) EPS. As a group, equities research analysts predict that Y-mAbs Therapeutics, Inc. will post -0.66 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on YMAB. Wedbush reissued an “outperform” rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. Brookline Capital Management initiated coverage on shares of Y-mAbs Therapeutics in a research note on Thursday, December 5th. They set a “buy” rating and a $17.00 price objective on the stock. HC Wainwright reiterated a “buy” rating on shares of Y-mAbs Therapeutics in a research note on Wednesday, December 11th. Oppenheimer began coverage on Y-mAbs Therapeutics in a report on Monday, November 18th. They set an “outperform” rating and a $23.00 price target for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, September 9th. One analyst has rated the stock with a sell rating, seven have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Y-mAbs Therapeutics has an average rating of “Buy” and a consensus price target of $20.89.

Y-mAbs Therapeutics Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.